Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Curr Opin Rheumatol. 2016 Jan;28(1):83–88. doi: 10.1097/BOR.0000000000000237

Table 1.

Summary of SSc clinical trials discussed in this review.

Trials analyzed Improvers Non-improvers Reference
Imatinib mesylate ND, but response signature overlapped with fibroproliferative subset NA Chung et al. 2009
Mycophenolate mofetil (MMF) Inflammatory Fibroproliferative Hinchcliff et al. 2013
Abatacept Inflammatory; patients with high baseline levels of CD28 signaling Normal-like; patient with low baseline levels of CD28 signaling Chakravarty et al. 2015
Nilotinib Intrinsic subset was variable; patients with high baseline levels of TGFBR/PDGFRB signaling Fibroproliferative; patients with low baseline levels of TGFBR/PDGFRB signaling Gordon et al. 2015

For each trial, information about improvers and non-improvers in terms of intrinsic subsets and relevant targeted pathways is provided (where applicable). NA – not available, ND – not determined.